| Clinical data | |
|---|---|
| ATC code |
|
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| IUPHAR/BPS | |
| ChemSpider | |
| UNII | |
| CompTox Dashboard(EPA) | |
| Chemical and physical data | |
| Formula | C24H20F3N3O |
| Molar mass | 423.439 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
RO-4491533 is adrug developed byHoffmann-La Roche which acts as apotent andselectivenegative allosteric modulator forgroup II of themetabotropic glutamate receptors (mGluR2/3), being equipotent at mGluR2 and mGluR3 but without activity at other mGluR subtypes. In animal studies, RO-4491533 producedantidepressant effects and reversed the effects of the mGluR2/3 agonistLY-379,268 with similar efficacy but slightly lower potency than the mGluR2/3 antagonistLY-341,495.[1] A number of related compounds are known, with similar effectsin vitro and a fairly well characterizedstructure-activity relationship.[2]
Thisdrug article relating to thenervous system is astub. You can help Wikipedia byexpanding it. |